Journal articles on the topic 'F. Hoffman-La Roche AG'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'F. Hoffman-La Roche AG.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Pott, Christiane, Eva Hoster, Britta Kehden, Michael Unterhalt, Michael Herold, Richard van der Jagt, Ann Janssens, et al. "Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients." Blood 132, Supplement 1 (November 29, 2018): 396. http://dx.doi.org/10.1182/blood-2018-99-115930.
Full textNishimura, Jun-ichi, Antoine Soubret, Simon Buatois, Jean-Eric Charoin, Sasha Sreckovic, Christoph Bucher, Jules Hernández-Sánchez, et al. "An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial." Blood 136, Supplement 1 (November 5, 2020): 2–3. http://dx.doi.org/10.1182/blood-2020-136265.
Full textSchmidt, Christian, Anna-Katharina Zoellner, Vindi Jurinovic, Martin Sökler, Roswitha Forstpointner, Sascha Haubner, Christian Buske, et al. "Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)." Blood 132, Supplement 1 (November 29, 2018): 448. http://dx.doi.org/10.1182/blood-2018-99-111692.
Full textVersmold, Katharina, Ferras Alashkar, Carina Raiser, Richard Ofori-Asenso, Tao Xu, Yutong Liu, Pablo Katz, Aijing Shang, and Alexander Roeth. "Clinical Profile and Long-Term Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab in a Real-World Setting: High Frequency of Anemia Despite Decreased Intravascular Hemolysis." Blood 138, Supplement 1 (November 5, 2021): 4314. http://dx.doi.org/10.1182/blood-2021-147162.
Full textLi, Chi-Chung, Brendan Bender, Shen Yin, Zao Li, Cindy Zhang, Genevive Hernandez, Antonia Kwan, et al. "Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma." Blood 134, Supplement_1 (November 13, 2019): 1285. http://dx.doi.org/10.1182/blood-2019-123961.
Full textAlig, Stefan, Alessandro Pastore, Vindi Jurinovic, Sarah Häbe, Deepak Bararia, Verena Passerini, William Keay, et al. "Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial." Blood 132, Supplement 1 (November 29, 2018): 4096. http://dx.doi.org/10.1182/blood-2018-99-118000.
Full textGrether, Uwe, and Julie Blaising. "MAGL inhibition: A novel treatment option for combating inflammatory disease?" Open Access Government 41, no. 1 (January 19, 2024): 48–49. http://dx.doi.org/10.56367/oag-041-11209.
Full textPhillips, Tycel J., Adam J. Olszewski, Javier Munoz, Tae Min Kim, Dok Hyun Yoon, Richard Greil, Jason Westin, et al. "Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma." Blood 136, Supplement 1 (November 5, 2020): 37–38. http://dx.doi.org/10.1182/blood-2020-136295.
Full textNégrier, Claude, Johnny Mahlangu, Michaela Lehle, Pratima Chowdary, Olivier Catalani, Víctor Jiménez-Yuste, Benjamin M. Beckermann, et al. "Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study." Blood 138, Supplement 1 (November 5, 2021): 343. http://dx.doi.org/10.1182/blood-2021-146009.
Full textKhair, Kate, Francis Nissen, Mariabeth Silkey, Tom Burke, Aijing Shang, Martynas Aizenas, Oliver Meier, Jamie O'Hara, and Declan Noone. "Effect of Moderate and Severe Hemophilia a on Daily Life in Children and Their Caregivers: A CHESS Paediatrics Study Analysis." Blood 136, Supplement 1 (November 5, 2020): 43–45. http://dx.doi.org/10.1182/blood-2020-134658.
Full textCaglayan, Caglar, Jesse Dixon, Anna Wall, Gilles A. Salles, Eva Hoster, Wolfgang Hiddemann, Michael Herold, et al. "A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group." Blood 134, Supplement_1 (November 13, 2019): 2812. http://dx.doi.org/10.1182/blood-2019-122328.
Full textHutchings, Martin, Fritz C. Offner, Francesc Bosch, Giuseppe Gritti, Carmelo Carlo-Stella, Harriet Walter, William Townsend, et al. "Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma." Blood 136, Supplement 1 (November 5, 2020): 16–17. http://dx.doi.org/10.1182/blood-2020-136571.
Full textSkinner, Mark W., Gillian Hanson, Tao Xu, Richard Ofori-Asenso, Richard H. Ko, Emily Cibelli, Francis Nissen, Michelle Witkop, Fabian Sanabria, and Amy D. Shapiro. "A Novel Methodology for Building Longitudinal, Patient-Centric Real World Datasets in Hemophilia A." Blood 138, Supplement 1 (November 5, 2021): 594. http://dx.doi.org/10.1182/blood-2021-146160.
Full textCastaman, Giancarlo, Jerzy Windyga, Hazza Alzahrani, Susan Robson, Fabian Sanabria, Monet Howard, and Víctor Jiménez-Yuste. "Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A with FVIII Inhibitors: Final Analysis." Blood 138, Supplement 1 (November 5, 2021): 344. http://dx.doi.org/10.1182/blood-2021-145890.
Full textWitkop, Michelle, Tao Xu, Gillian Hanson, Richard Ofori-Asenso, Richard H. Ko, Emily Cibelli, Martynas Aizenas, Mark W. Skinner, Fabian Sanabria, and Amy D. Shapiro. "Characterizing Mild and Moderate Hemophilia A Patients in the Real World: A Patient-Centric Approach." Blood 138, Supplement 1 (November 5, 2021): 2107. http://dx.doi.org/10.1182/blood-2021-146543.
Full textSeymour, John F., Thomas J. Kipps, Barbara F. Eichhorst, Peter Hillmen, James D'Rozario, Sarit Assouline, Carolyn Owen, et al. "Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)." Blood 134, Supplement_1 (November 13, 2019): 355. http://dx.doi.org/10.1182/blood-2019-123930.
Full textJiráčková, Jana, Radomir Hyšpler, Sumaya Alkanderi, Ladislava Pavlíková, Vladimir Palicka, and John A. Sayer. "Novel CYP24A1 Mutation in a Young Male Patient with Nephrolithiasis: Case Report." Kidney and Blood Pressure Research 44, no. 4 (2019): 870–77. http://dx.doi.org/10.1159/000500922.
Full textJurinovic, Vindi, Verena Passerini, Mikkel Z. Oestergaard, Andrea Knapp, Kirsten Mundt, Shamzah Araf, Julia Richter, et al. "Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy." Blood 134, Supplement_1 (November 13, 2019): 122. http://dx.doi.org/10.1182/blood-2019-130208.
Full textDuncan, Ian, Natalie Danziger, Daniel Duncan, Amanda Hemmerich, Claire Edgerly, Richard Huang, Jo-Anne Vergilio, et al. "Acid-Based Decalcification Methods Compromise Genomic Profiling from DNA and RNA." Blood 134, Supplement_1 (November 13, 2019): 4659. http://dx.doi.org/10.1182/blood-2019-131362.
Full textMassoth, Lucas R., Yin P. Hung, Judith A. Ferry, Robert P. Hasserjian, Abner Louissaint, Meagan Montesion, Ethan S. Sokol, et al. "Comprehensive Genomic Profiling of 104 Rare Histiocytic and Dendritic Cell Neoplasms Reveals Shared and Distinct Targetable Genomic Alterations." Blood 134, Supplement_1 (November 13, 2019): 2541. http://dx.doi.org/10.1182/blood-2019-123729.
Full textJaeger, Ulrich, Michael R. Bishop, Gilles Salles, Stephen J. Schuster, Richard T. Maziarz, Xia Han, Alexander Savchenko, et al. "Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial." Blood 136, Supplement 1 (November 5, 2020): 48–49. http://dx.doi.org/10.1182/blood-2020-137045.
Full textSostelly, Alexandre, Simon Buatois, Antoine Soubret, Erica Winter, Barbara Klughammer, Joy C. Hsu, Gregor Jordan, et al. "Exposure-Response Relationship of the SMART-Ig Anti-hC5 Antibody Crovalimab (SKY59): Results from the Umbrella Phase 1/2 Composer Trial in Healthy Volunteers and PNH Patients." Blood 134, Supplement_1 (November 13, 2019): 3745. http://dx.doi.org/10.1182/blood-2019-124258.
Full textSeverson, Eric A., Ethan S. Sokol, Russell Madison, Daniel Duncan, Amanda Hemmerich, Claire Edgerly, Richard Huang, et al. "Loss of Heterozygosity of FLT3-ITD Is Common in Acute Myeloid Leukemia and May be a More Consistent Prognostic Marker Than FLT3-ITD Allele Frequency." Blood 134, Supplement_1 (November 13, 2019): 1437. http://dx.doi.org/10.1182/blood-2019-131248.
Full textHuntington, Scott F., Avyakta Kallam, Frank G. Basile, Danielle Ulanet, Huansheng Xu, Feng Yin, Michelle Mobilia, et al. "AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study." Blood 134, Supplement_1 (November 13, 2019): 1286. http://dx.doi.org/10.1182/blood-2019-123420.
Full textAl-Sawaf, Othman, Can Zhang, Sandra Robrecht, Anna-Maria Fink, Paula Cramer, Carmen D. Herling, Julia Von Tresckow, et al. "Severe Infections in Patients with Chronic Lymphocytic Leukemia Treated with (Immuno-)Chemotherapy: A Pooled Analysis of Gcllsg Trials." Blood 136, Supplement 1 (November 5, 2020): 18–19. http://dx.doi.org/10.1182/blood-2020-139242.
Full textJimenez-Yuste, Victor, Midori Shima, Katsuyuki Fukutake, Michaela Lehle, Sammy Chebon, Sylvie Retout, Agnès Portron, and Gallia G. Levy. "Emicizumab Subcutaneous Dosing Every 4 Weeks for the Management of Hemophilia A: Preliminary Data from the Pharmacokinetic Run-in Cohort of a Multicenter, Open-Label, Phase 3 Study (HAVEN 4)." Blood 130, Suppl_1 (December 7, 2017): 86. http://dx.doi.org/10.1182/blood.v130.suppl_1.86.86.
Full textEsatoglu, S. N., B. Tukek, S. S. Taflan, Y. Ozyazgan, D. Ucar, V. Hamuryudan, Y. Ozguler, et al. "POS0816 DRUG SURVIVAL OF INFLIXIMAB IN BEHÇET’S SYNDROME PATIENTS WITH DIFFERENT TYPES OF INVOLVEMENT." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 697.2–698. http://dx.doi.org/10.1136/annrheumdis-2022-eular.3951.
Full textHusar, Elisabeth, Maria Solonets, Olaf Kuhlmann, Eginhard Schick, Hanna Piper-Lepoutre, Thomas Singer, and Gaurav Tyagi. "Hypersensitivity Reactions to Obinutuzumab in Cynomolgus Monkeys and Relevance to Humans." Toxicologic Pathology 45, no. 5 (July 2017): 676–86. http://dx.doi.org/10.1177/0192623317723539.
Full textSchuster, Michael W., Miguel A. Canales, Jason Westin, Josée M. Zijlstra, George A. Follows, Reem Karmali, Nagesh Kalakonda, et al. "Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study." Blood 136, Supplement 1 (November 5, 2020): 34–35. http://dx.doi.org/10.1182/blood-2020-137025.
Full textZeng, Zhihong, Natalia Baran, Sergej Konoplev, Antonio Cavazos, Qi Zhang, Vinitha Mary Kuruvilla, Philip Lorenzi, et al. "Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and in Vivo." Blood 134, Supplement_1 (November 13, 2019): 3911. http://dx.doi.org/10.1182/blood-2019-125469.
Full textShima, Midori, Sayaka Nagami, Koichiro Yoneyama, Akira Nomura, Yoshiyuki Ogawa, Kagehiro Amano, and Keiji Nogami. "An Investigational Dosing Algorithm of Emicizumab for Prophylaxis in Acquired Hemophilia a." Blood 136, Supplement 1 (November 5, 2020): 26–27. http://dx.doi.org/10.1182/blood-2020-136488.
Full textNicklaus, Mr Karl, and Dr Martin Schadt. "Entrepreneur acquires Rolic Ltd from F. Hoffman-La Roche." Liquid Crystals Today 7, no. 2 (June 1997): 10. http://dx.doi.org/10.1080/13583149708047668.
Full textWang, Rongrong, Josh Roth, Carmen Ng, Farah Hossain, Jia Li, and Anthony Masaquel. "Cost of Disease Progression after Frontline (1L) R-CHOP in Diffuse Large B-Cell Lymphoma (DLBCL)." Blood 138, Supplement 1 (November 5, 2021): 3002. http://dx.doi.org/10.1182/blood-2021-146802.
Full textSostelly, Alexandre, Antoine Soubret, Christoph Bucher, Simon Buatois, Jean-Eric Charoin, Gregor Jordan, Barbara Klughammer, et al. "Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes." Blood 134, Supplement_1 (November 13, 2019): 1227. http://dx.doi.org/10.1182/blood-2019-126911.
Full textJulia, Edith, Nathan H. Fowler, Emmanuel Bachy, Pierre Feugier, Reda Bouabdallah, Herve Tilly, M. Lia Palomba, et al. "Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial." Blood 134, Supplement_1 (November 13, 2019): 1524. http://dx.doi.org/10.1182/blood-2019-129024.
Full textSen, P., N. R, A. Nune, J. B. Lilleker, V. Agarwal, S. Kardes, M. Kim, et al. "POS1260 COVID-19 VACCINATION-RELATED ADVERSE EVENTS AMONG AUTOIMMUNE DISEASE PATIENTS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 966–67. http://dx.doi.org/10.1136/annrheumdis-2022-eular.4197.
Full textGupta, L., L. S. Hoff, N. R, P. Sen, S. Katsuyuki Shinjo, J. Day, J. B. Lilleker, et al. "POS0201 COVID-19 SEVERITY AND VACCINE BREAKTHROUGH INFECTIONS IN IDIOPATHIC INFLAMMATORY MYOPATHIES, OTHER SYSTEMIC AUTOIMMUNE AND INFLAMMATORY DISEASES, AND HEALTHY INDIVIDUALS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 334–36. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2160.
Full textTyanova, Stefka, Tao Xu, Mellissa Williamson, Alberto Rocci, Wan-Jen Hong, Huan Jin, Sudeep Karve, James Roose, Ahmed Sawas, and Shaji Kumar. "Lab-Based Response Assessment Algorithm Recapitulates Investigator's Response Assessment in the Phase 3 Bellini Trial." Blood 138, Supplement 1 (November 5, 2021): 4758. http://dx.doi.org/10.1182/blood-2021-147713.
Full textSchuster, Michael W., Miguel A. Canales, Jason Westin, Josée M. Zijlstra, George A. Follows, Reem Karmali, Nagesh Kalakonda, et al. "Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study." Blood 136, Supplement 1 (November 5, 2020): 5–6. http://dx.doi.org/10.1182/blood-2020-137020.
Full textXu, Tao, Stefka Tyanova, Mellissa Williamson, Alberto Rocci, Kasra Yousefi, and Shaji Kumar. "Assessment of Associations between Derived Response and Overall Survival in Patients with Multiple Myeloma Using a US-Based Electronic Health Records Database." Blood 138, Supplement 1 (November 5, 2021): 3770. http://dx.doi.org/10.1182/blood-2021-150148.
Full textThieblemont, Catherine, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Jason P. Butler, Monalisa Ghosh, Leslie L. Popplewell, et al. "Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study." Blood 138, Supplement 1 (November 5, 2021): 131. http://dx.doi.org/10.1182/blood-2021-145025.
Full textAndrie, Rachael M., John M. Burke, Christopher R. Flowers, Nathan H. Fowler, Jeff P. Sharman, Timothy A. Quill, Kevin L. Obholz, and Ian W. Flinn. "Analysis of an Online Treatment Decision Tool Reveals Variances in Practice between Experts and Oncology Healthcare Providers for Newly Diagnosed Follicular Lymphoma." Blood 134, Supplement_1 (November 13, 2019): 414. http://dx.doi.org/10.1182/blood-2019-128988.
Full textVachhani, Pankit, Jonathan A. Abbas, Evelyn M. Flahavan, Esprit Ma, Tao Xu, Huan Jin, Melissa Montez, et al. "Real World Treatment Patterns and Outcomes of Venetoclax (Ven) and Hypomethylating Agents (HMA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States." Blood 138, Supplement 1 (November 5, 2021): 2290. http://dx.doi.org/10.1182/blood-2021-147851.
Full textBarrington, Sally F., Judith Trotman, Deniz Sahin, David Belada, Andrew Davies, Robert MacEwan, Carolyn Owen, et al. "Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study." Blood 132, Supplement 1 (November 29, 2018): 2882. http://dx.doi.org/10.1182/blood-2018-99-117235.
Full textKostakoglu, Lale, Paola Berchialla, Federico Dalmasso, Larry A. Pierce, Umberto Vitolo, Maurizio Martelli, Laurie H. Sehn, et al. "A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA." Blood 134, Supplement_1 (November 13, 2019): 883. http://dx.doi.org/10.1182/blood-2019-123450.
Full textClemow, D. B., C. Sapin, T. Hibi, M. C. Dubinsky, S. Vermeire, S. Schreiber, T. H. Gibble, et al. "A186 ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION." Journal of the Canadian Association of Gastroenterology 6, Supplement_1 (March 1, 2023): 31–32. http://dx.doi.org/10.1093/jcag/gwac036.186.
Full textClay, E. Leila Jerome, Miranda Bailey, Dan Drozd, Jincy Paulose, Nicholas Ramscar, Kieran Mace, and David Wormser. "A Patient-Centric Approach to Improve the Understanding of Sickle Cell Disease Using Real-World Data." Blood 136, Supplement 1 (November 5, 2020): 27–28. http://dx.doi.org/10.1182/blood-2020-139148.
Full textJaeger, Ulrich, Alexander Egle, Ingrid Simonitsch-Klupp, Sonja Heibl, Peter Neumeister, Ella Willenbacher, Florian Erlsbacher, Julian Larcher-Senn, Michael A. Fridrik, and Richard Greil. "Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study." Blood 136, Supplement 1 (November 5, 2020): 26. http://dx.doi.org/10.1182/blood-2020-136953.
Full textSiddiqi, Tanya, Ulrich Jaeger, Olga Moshkovich, Jennifer Devlen, Matthew Miera, Agnes Williams, Jens Hasskarl, Fei Fei Liu, Julia Braverman, and Gilles Salles. "Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy." Blood 136, Supplement 1 (November 5, 2020): 22–23. http://dx.doi.org/10.1182/blood-2020-137656.
Full textCallaghan, Michael U., Claude Négrier, Ido Paz-Priel, Tiffany Chang, Sammy Chebon, Michaela Lehle, Johnny Mahlangu, et al. "Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)." Blood 136, Supplement 1 (November 5, 2020): 3–5. http://dx.doi.org/10.1182/blood-2020-137438.
Full text